Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVID: U-500 Insulin CSII vs MDI in T2DM
NCT02561078Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of insulin regular human U-500 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Hemoglobin A1c at 26 weeks. Started Oct 2015; status: completed.
02
Drugs
insulin regular human U-500
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02561078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561078.